Moscow, September 20, 2013 - Pharmstandard OJSC (the “Company”) announces additional details for voting at the Extraordinary General Shareholder’s Meeting of Pharmstandard OJSC (“EGM”) that it is considering a spin-off of the Company’s branded over-the-counter business into a separate legal entity (“Reorganisation”). EGM will take place on September 27, 2013.
The list of shareholders entitled to vote was formed as of July 5, 2013.
The last date for submitting votes is September 25, 2013.
The last date for Holders of GDRs to instruct Depositary to submit voting rights is September 23, 2013
“FOR”. If the spin-off is approved, Shareholders who vote FOR shall receive ordinary registered shares of the Newly Created Company (“NewCo”) granting the rights identical to those granted by ordinary registered shares such person holds in the Company, in the number pro rata to the number of Company ordinary shares held by such Shareholder.
“AGAINST”. If spin-off approved, Shareholders who vote AGAINST will have the option to sell their shares in the Company to the Company (“Buyout”) and shall receive ordinary registered shares of the NewCo granting the rights identical to those granted by ordinary registered shares such person holds in the Company, in the number pro rata to the number of Company ordinary shares held by such Shareholder, less ordinary Company shares which the Company is demanded to buy out and which would be bought out pursuant to the Law of Joint-Stock Companies.
“ABSTAIN”. If spin-off approved, Shareholders who vote ABSTAIN will NOT have the opportunity to participate in the Buyout, but shall receive ordinary registered shares of the NewCo granting the rights identical to those granted by ordinary registered shares such person holds in the Company, in the number pro rata to the number of Company ordinary shares held by such Shareholder.
“No vote”. If spin-off approved, Shareholders who fail to vote will have the option to participate in the Buyout and shall receive ordinary registered shares of the NewCo granting the rights identical to those granted by ordinary registered shares such person holds in the Company, in the number pro rata to the number of Company ordinary shares held by such Shareholder, less ordinary Company shares which the Company is demanded to buy out and which would be bought out pursuant to the Law of Joint-Stock Companies.
Regards,
Irina Bakhturina
Head of Investor Relations
Pharmstandard OJSC
Tel. (495) 970-0030 ext.2824
Fax (495) 970-0032
www.pharmstd.ru
| Back | Print out |
